The Patent Finder

Rottapharm Biotech S.R.L.

Also on record
Records under this name other than the patents Rottapharm Biotech S.R.L. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 9 patents it holds.

Back to Rottapharm Biotech S.R.L.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,994,1816-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents
Term ended
Term ended Aug 3, 2026 · USPTO record
Term endedTerm ended Aug 3, 2026USPTO record
US 8,193,3536-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents
Term ended
Term ended Aug 3, 2026 · USPTO record
Term endedTerm ended Aug 3, 2026USPTO record
US 8,633,2086-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands
Lapsed on the fee record
Ended Jan 21, 2026 · USPTO record
Lapsed on the fee recordEnded Jan 21, 2026USPTO record
US 9,120,824Cyclic amine derivatives as EP4 receptor agonists
Lapsed on the fee record
Ended Sep 1, 2023 · USPTO record
Lapsed on the fee recordEnded Sep 1, 2023USPTO record
US 7,968,558Amidine derivatives of 2-heteroaryl-quinazolines and quinolines; potent analgesics and anti-inflammatory agents
Lapsed on the fee record
Ended Jun 28, 2023 · USPTO record
Lapsed on the fee recordEnded Jun 28, 2023USPTO record
US 9,062,033Chemical compounds
Lapsed on the fee record
Ended Jun 23, 2023 · USPTO record
Lapsed on the fee recordEnded Jun 23, 2023USPTO record
US 8,859,608Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
Lapsed on the fee record
Ended Oct 14, 2022 · USPTO record
Lapsed on the fee recordEnded Oct 14, 2022USPTO record
US 8,828,987Pyridine amide derivatives as EP4 receptor antagonists
Lapsed on the fee record
Ended Sep 9, 2022 · USPTO record
Lapsed on the fee recordEnded Sep 9, 2022USPTO record
US 7,674,809Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production
Lapsed on the fee record
Ended Mar 9, 2022 · USPTO record
Lapsed on the fee recordEnded Mar 9, 2022USPTO record
US 9,631,029Anti-ADAMTS-5 antibody, derivatives and uses thereof
Lapsed on the fee record
Ended Apr 25, 2021 · USPTO record
Lapsed on the fee recordEnded Apr 25, 2021USPTO record
10 of 35 patents shown.
Pro members see all 35.
Pro members: see all 35 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited